CTOs on the Move

Merck Sharp and Dohme

www.sirna.com

 
Merck Sharp and Dohme Corp. is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.sirna.com
  • 1700 Owens St
    San Francisco, CA USA 94158
  • Phone: 415.512.7200

Executives

Name Title Contact Details

Similar Companies

Orchid Orthopedic Solutions

Orchid Orthopedic Solutions is a Holt, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Standards Testing Bureau

American Standards Testing Bureau is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fortus Healthcare Resources

For more than 20 years, Fortus Healthcare Resources has embraced a personalized approach to recruiting. With a candidate database unmatched in the industry, we value our relationship with clients and candidates. The Fortus Group is the pioneer of dialysis recruitment. Since 1993, we have been committed to providing recruitment solutions for the dialysis industry with much success and growth. Our organization has expanded from a one-desk specialty recruiter to a state-of-the-art facility. With a staff of over 30, we continue to maintain the largest recruiting staff industrywide. Our company`s 100+ years combined dialysis recruiting experience enables us to provide the best possible means for candidates to fulfill their goals. In 2006, our services expanded from permanent placement of dialysis and transplantation professionals to the placement of travel nurses. With flexible, competitive salary and benefit packages, Fortus Group Travel offers the healthcare industry temporary staffing relief, while providing nurses with unlimited travel opportunities. The Fortus Group continues to build on its strong foundation of quality resources and dedicated relationships. The success of our company is based on bringing together the highest quality career consultants dedicated to providing outstanding opportunities to our specialized industry.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.

Abridge

Abridge helps people stay on top of their health, one conversation at a time. We help people capture the details of their care so they can follow through on doctor`s recommendations and gain more peace of mind throughout their health journey.